← ANALYST RATINGS · TIPRANKS
Corbus Pharmaceuticals (CRBP): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $36.67, the highest $48.00, the lowest $30.00. The average is +711.2% from the last price of $4.52.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $5.00 → $4.50−10.0% | Hold | −0.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Hold | −11.5% | Upgrade | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $5.00 → $4.50−10.0% | Hold | −0.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $5.50 → $4.50−18.2% | Hold | −0.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $5.00 → $4.50−10.0% | Hold | −0.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $5.50 → $4.50−18.2% | Hold | −0.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $30.00 | Buy | +563.7% | Reiterated | 15.09.26on TipRanks 08:10 | −13.9%next day +5.4% · 5 days +11.4% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $35.00 | Buy | +674.3% | Reiterated | 15.09.26on TipRanks Sep 14 12:15 | 0.0%next day −13.9% · 5 days −7.2% | ↗ |
| Andy Hsieh★★★★★★★★★★#1805 · hits 48% · avg +9.0% | William Blair | — | Buy | — | Reiterated | 14.09.26on TipRanks 12:06 | 0.0%next day −13.9% · 5 days −7.2% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $38.00 | Buy | +740.7% | Reiterated | 14.09.26on TipRanks 11:35 | 0.0%next day −13.9% · 5 days −7.2% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $33.00 | Buy | +630.1% | Reiterated | 14.09.26on TipRanks 08:15 | 0.0%next day −13.9% · 5 days −7.2% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $36.00 | Buy | +696.5% | Reiterated | 12.08.26on TipRanks 07:05 | +2.4%next day +2.6% · 5 days +2.8% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $52.00 → $48.00−7.7% | Buy | +961.9% | Reiterated | 07.08.26on TipRanks 08:20 | +3.8%next day −7.0% · 5 days −1.2% | ↗ |
| Paul Jeng★★★★★★★★★★#9457 · hits 52% · avg −1.9% | Guggenheim | $45.00 | Buy | +895.6% | Reiterated | 02.06.26on TipRanks 07:16 | −2.8%next day −1.4% · 5 days +5.1% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $36.00 → $33.00−8.3% | Buy | +630.1% | Reiterated | 12.05.26on TipRanks 16:10 | +5.7%next day −2.2% · 5 days −19.8% | ↗ |
| Unknown Analyst | B. Riley Securities | $28.00 | Buy | +519.5% | Reiterated | 10.04.26on TipRanks Apr 24 21:02 | −5.0%next day +2.9% · 5 days +3.5% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $35.00 → $51.00+45.7% | Buy | +1,028.3% | Reiterated | 20.10.25on TipRanks 09:00 | −6.4%next day +5.9% · 5 days −9.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Corbus Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $36.67 at a price of $6.82 (+437.6%); now: $36.67 at $4.52 (+711.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 24 | 23 | 18 | 11 | 12 | 12 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.21 (from $-1.91 to $-0.73). Last quarter: $-1.81.
Best top-analyst consensus in the sector · Healthcare
About Corbus Pharmaceuticals
- CEO: Yuval Cohen
- Employees: 36
- 500 River Ridge Drive, Norwood, MA, 02062, US
- www.corbuspharma.com
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Data from the stock’s TipRanks forecast page, read 20 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗